An open-label pilot study of levetiracetam for essential tremor

Clinical Neuropharmacology

Volumn 27, Issue 6, 2004, Pages 274-277

  Ondo, William G ^a   Jimenez, J Ernesto ^a   Vuong, Kevin Dat ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Essential tremor; Levetiracetam; Open label trial

Indexed keywords

ETIRACETAM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ESSENTIAL TREMOR; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NERVOUSNESS; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; SEDATION; SIDE EFFECT;

AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESSENTIAL TREMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PILOT PROJECTS; PIRACETAM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 11244270429     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200411000-00004     Document Type: Article

References (18)

1. Louis ED, Marder K, Cote L, et al. Prevalence of a history of shaking in persons 65 years of age and older: diagnostic and functional correlates. Mov Disord. 1996;11:63-69.
2. Lyons K, Pahwa R, Comelia C, et al. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003;26:461-481.
3. Ondo WG, Hunter C, Schwartz K, et al. High dose gabapentin for essential tremor: a double blind, placebo controlled, cross-over trial. Mov Disord. 2000;15:678-682.
4. Conner GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology. 2002;59:132-134.
5. Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523-1528.
6. Koller W, Pahwa R, Busenbark K. High frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 1997;42:292-299.
7. Limousin P, Speelman JD, Gielen F, et al. Multicenter European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry. 1999;66:289-296.
8. Pahwa R, Lyons K, Wilkinson S, et al. Bilateral thalamic stimulation for the treatment of essential tremor. Neurology. 1999;53:1447-1450.
9. Frucht SJ, Louis ED, Chuang C, et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology. 2001;57:1112-1114.
10. Shorvorn SD. Pyrrolidine derivatives. Lancet. 2001;200:1885-1892.
11. Poulin P, Margineanu DG. Levetiracetam opposes the action of GABA(A) antagonists in hypothalamic neurons. Neuropharmacology. 2002;42:346-352.
12. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43:9-18.
13. Madeja M, Margineanu D, Klitgaard H. Effects of levetiracetam on voltage gaited, potassium channels: a novel anti-epileptic mechanism? Epilepsia. 2001;42(suppl 2):19.
14. Margineanu D, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical anti-epileptic drugs. Pharmacol Res. 2000;42:281-285.
15. Elble RJ. Diagnostic criteria for essential tremor and differential diagnosis. Neurology. 2000;54(suppl 4):S2-S6.
16. Fahn S, Tolosa E, Conceppcion M. Clinical rating scale for tremor. In Parkinsons Disease and Movement Disorders. Edited by Jankovic J, Tolosa E. Baltimore: Williams and Wilkins; 1993:271-280.
17. Ondo W, Hunter C, Vuong K, et al. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15:678-682.
18. Bain PG, Findley LJ, Atchison P, et al. Assessing tremor severity. J Neurol Neurosurg Psychiatry. 1993;56:868-873.